Phase 1 study of YM155, novel selective survivin suppressant in combination with elrotinib in patients with EGFR-mutant advanced non-small-cell lung cancer
- Conditions
- on-small-cell lung cancer
- Registration Number
- JPRN-UMIN000031912
- Lead Sponsor
- Department of Medical Oncology, Kindai University Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Not provided
The exclusion criteria included the administration of chemotherapy, radiotherapy, or biological therapy in the 4 weeks, 2 weeks for palliative radiotherapy and kinase inhibitors prior to enrollment Other active malignancies; history or presence of interstitial lung disease; presence of symptomatic brain metastasis; history within 6 months before enrollment or presence of severe cardiovascular or cerebrovascular disease, pulmonary thrombosis, deep vein thrombosis, or other clinically severe pulmonary disease; any of the following complications, including clinically severe infections requiring systemic administration of an antimicrobial agent, antiviral agent or other agents; presence of chronic diarrhea, inflammatory bowel disease or partial ileus; presence of peptic ulcer; fluid retention requiring treatment; uncontrolled diabetes mellitus/hypertension; psychiatric symptoms; appositive test for hepatitis B virus surface antigen, hepatitis C virus antibody or human immunodeficiency virus antibody.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method